Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03502330
Recruitment Status : Recruiting
First Posted : April 18, 2018
Last Update Posted : December 22, 2020
Bristol-Myers Squibb
Apexigen, Inc.
Information provided by (Responsible Party):
Yale University

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : May 2022
Estimated Study Completion Date : October 2024